Valencia, Ca., USA - April 21, 2016, Valencia, Ca., USA - MannKind Corporation, a biopharmaceutical company, appoints Joseph Saldanha as vice president of marketing and Agustin Quintero as vice president of market value, access and trade.
Article continues below
Mr. Saldanha has worked in the diabetes space for over 13 years, in both U.S. and global roles. He has experience marketing oral anti-diabetic medications, insulins (both injectable and inhaled), and medical devices.
Mr. Saldanha commercialized Sanofi's Lantus in the Intercontinental Region. After returning to the U.S., he was part of the team that commercialized the Lantus SoloSTAR pen.
In addition to heading up Sanofi's strategy and medical education teams, he was responsible for all hospital business. Mr. Saldanha launched an initiative with Certified Diabetes Educators to train patients in diabetes and the appropriate use of insulin.
Prior to that, he served as Director of Business Development for the insulin delivery device business at Johnson and Johnson Diabetes (LifeScan/Animas). More recently, he worked in the biosimilars business with Pfizer in New York.
Mr. Saldanha holds a Bachelor of Science from Drexel University and a Master of Science from the University of Pennsylvania.
Mr. Quintero has 18 years of experience in bio-pharmaceutical market access as well as a proven record of achieving commercial excellence. He joins MannKind from AbbVie, a global biopharmaceutical company, where he served as National Managed Care Executive.
In this role, Mr. Quintero was responsible for negotiating AbbVie's portfolio of products (including Humira) while developing contracting and pricing strategies for hepatitis C, multiple sclerosis and oncology product launches.
Prior to that, he held integral leadership roles in sales and account management at Vertex Pharmaceuticals, including oversight of the commercial launch of Incivek, their first commercial product.
Earlier, he was part of Gilead Sciences and Sandoz's leadership teams, responsible for sales, product launches and market access for both commercial and government payers. ■